抗凝治疗是复杂的,具有实质性获益(在急性疾病和之后静脉血栓栓塞[VTE]复发的情况下,血栓进展和致死性肺栓塞[PE]的风险降低)和风险(危及生命的出血并发症)[1]。
登录后 PLUS 会员 可查看完整内容
微信扫一扫
成为会员后
查看完整内容
文献评审日期:2021-05-31
1. Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism [published correction appears in J Thromb Thrombolysis. 2016;42(2):296-311]. J Thromb Thrombolysis. 2016;41(1):15-31.
2. Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost. 2005;3(1):100-102.
3. Cosmi B, Filippini M, Tonti D, et al; STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost. 2012;10(6):1026-1035.
肺血栓栓塞症诊治与预防指南(2018)
2020 ASH指南:静脉血栓栓塞的管理—深静脉血栓形成和肺栓塞的治疗
医院内静脉血栓栓塞症防治质量评价与管理指南(2022版)